Inhibitory effect of mutant cytosine deaminase D314A against human colon cancer cells

Chinese Journal of Cancer Biotherapy

Volumn 16, Issue 6, 2009, Pages 595-599

  Sun, Mao Cai ^a   Huang, Yi Ming ^a   Zhu, Zheng Cai ^a   Wang, Jian Ping ^a   Shen, Li Zong ^a   Wu, Wen Xi ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Colon neoplasms; Cytosine deaminase; Site directed mutation; Suicide gene therapy

Indexed keywords

CYTOSINE DEAMINASE; MUTANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; ESCHERICHIA COLI; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN;

EID: 77953386621     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: 10.3872/j.issn.1007-385X.2009.06.008     Document Type: Article

References (20)

1. Altaner C. Prodrug cancer gene therapy [J]. Cancer Lett, 2008, 270(2): 191-201.
2. Park JI, Cao L, Piatt VM, et al. Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase [J]. Mol Pharm, 2009, 6(3): 801-812.
3. You MH, Kim WJ, Shim W, et al. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model [J]. J Gastroenterol Hepatol, 2009, 24 (8): 1393-1400.
4. Shen LZ, Wu WX, Xu DH, et al. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene [J]. World J Gastroenterol, 2002, 8(2): 270-275.
5. Chinese source
6. Kumar S, Brown SL, Kolozsvary A, et al. Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells [J]. J Neurooncol, 2008, 90(1): 19-24.
7. Lee CH, Wu CL, Shiau AL. Hypoxia-induced cytosine deaminase gene expression for cancer therapy [J]. Hum Gene Ther, 2007, 18(1): 27-38.
8. Lv SQ, Zhang KB, Zhang EE, et al. Antitumor efficiency of the cytosine deaminase/5 -fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study [J]. Med Sci Monit, 2009, 15(1): BR13-20.
9. Mahan SD, Ireton GC, Stoddard BL, et al. Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference [J]. Biochemistry, 2004, 43(28): 8957-8964.
10. Mahan SD, Ireton GC, Knoeber C, et al. Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy [J]. Protein Eng Des Sel, 2004, 17(8): 625-633.
11. Kaliberov SA, Market JM, Gillespie GY, et al. Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma [J]. Gene Ther, 2007, 14(14): 1111-1119.
12. Tseng WC, Lin JW, Wei TY, et al. A novel megaprimed and ligase-free, PCR-based, site-directed mutagenesis method [J]. Anal Biochem, 2008, 375(2): 376-378.
13. Zheng L, Baumann U, Reymond JL. An efficient one-step site-directed and site-saturation mutagenesis protocol [J]. Nucleic Acids Res, 2004, 32(14): e115.
14. Chinese source
15. Chinese source
16. Kaliberova LN, Della Manna DL, Krendelchtchikova V, et al. Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene [J]. Mol Cancer Ther, 2008, 7 (9): 2845-2854.
17. Tanaka T, Duflot-Dancer A, Tiraby M, et al. Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: a partial contribution of gap junctions [J]. Cancer Lett, 2009, 282(1): 4347.
18. Freytag SO, Barton KN, Brown SL, et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer [J]. Mol Ther, 2007, 15(9): 1600-1606.
19. Khatri A, Husaini Y, Ow K, et al. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines [J]. Clin Cancer Res, 2009, 15(7): 2323-2334.
20. Fuchita M, Ardiani A, Zhao L, et al. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluoro-cytosine- mediated cell killing in vitro and in vivo [J]. Cancer Res, 2009, 69(11): 47914799.